0000000000739398

AUTHOR

Luc Cormier

showing 18 related works from this author

Photovaporisation prostatique au laser Greenlight® : comparaison des couts (microcosting) et des recettes (t2a)

2016

Objectifs Depuis une vingtaine d’annees, la chirurgie de l’HBP est marquee par le developpement de techniques lasers sans GHS specifique necessitant un dispositif medical couteux ( fibre laser ) non rembourse en sus des GHS. L’objectif a ete d’evaluer le cout d’une telle intervention en hospitalisation complete afin de le comparer aux recettes percues (GHS) et aux couts estimes par l’etude nationale des couts a methodologie commune (ENCC). Methodes C’est une etude prospective, observationnelle et descriptive des couts de prise en charge. Les ressources medicales directes et indirectes ont ete identifiees et valorisees. Chaque sejour a ete decompose en deux periodes. Les couts de la phase pe…

business.industryUrologyMedicinebusinessHumanitiesProgrès en Urologie
researchProduct

Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: Who, when, where and how?

2014

Even in the current era of dose-escalated radiotherapy for prostate cancer, biochemical recurrence is not uncommon. Furthermore, biochemical failure is not specific to the site of recurrence. One of the major challenges in the management of prostate cancer patients with biochemical failure after radiotherapy is the early discrimination between those with locoregional recurrence only and those with metastatic disease. While the latter are generally considered incurable, patients with locoregional disease may benefit from emerging treatment options. Ultimately, the objective of salvage therapy is to control disease while ensuring minimal collateral damage, thereby optimizing both cancer and t…

MaleQuality ControlOncologyBiochemical recurrencemedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.medical_treatmentBrachytherapyBrachytherapySalvage therapyBone Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineAdenocarcinomaRadiosurgeryMultimodal Imaging[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicineManagement of prostate cancerProstate cancerInternal medicinemedicineHumansMulticenter Studies as TopicRadiology Nuclear Medicine and imagingComputingMilieux_MISCELLANEOUSProstatectomySalvage TherapyLymphatic Irradiationbusiness.industryPalliative CareProstatic NeoplasmsCancerAndrogen AntagonistsRadiotherapy DosageProstate-Specific Antigenmedicine.diseaseCombined Modality Therapy3. Good healthRadiation therapyProstate-specific antigenOncologyLymphatic MetastasisDose Fractionation RadiationRadiotherapy Intensity-ModulatedNeoplasm Recurrence LocalbusinessRadiotherapy Image-Guided
researchProduct

Robot-assisted or pure laparoscopic nerve-sparing radical prostatectomy: What is the optimal procedure for the surgical margins? A single center expe…

2012

Objectives:  To compare positive surgical margin rates after robot-assisted and pure laparoscopic radical prostatectomy when neurovascular bundles are preserved, and to identify parameters affecting surgical margin status. Methods:  From March 2004 to January 2009, 279 consecutive prostatectomies with preservation of neurovascular bundles were carried out by the same surgeon: 175 robot-assisted radical prostatectomies and 104 laparoscopic radical prostatectomies. An intraperitoneal Montsouris's technique was used for all cases. Patient's age, body mass index, prostate weight, prostate-specific antigen level, clinical stage, preoperative and postoperative Gleason score, percentage of positiv…

medicine.medical_specialtySurgical marginLaparoscopic radical prostatectomyProstatectomybusiness.industryUrologymedicine.medical_treatmentUrologySingle CenterNeurovascular bundleSurgerymedicine.anatomical_structureProstatemedicinePositive Surgical MarginStage (cooking)businessInternational Journal of Urology
researchProduct

Multiparametric MRI and post implant CT-based dosimetry after prostate brachytherapy with iodine seeds: The higher the dose to the dominant index les…

2015

Abstract Purpose To determine whether post-implant MRI-based dosimetry of the Dominant Intra-prostatic Lesion (DIL) could best predict the occurrence of PSA bounce after prostate brachytherapy. Methods and materials We selected 66 patients with a low risk prostate cancer treated with 125 I prostate brachytherapy as monotherapy. Post-implant dosimetry based on day 30 CT-scan and multiparametric MRI co-registration was generated: planned D 90, D 95, V 100, V 150 values were calculated for each DIL. Bounce was defined as a PSA elevation ⩾0.2ng/mL from the previous baseline value followed by a decrease to or below the prior nadir with no additional treatment. Results After a median follow-up of…

Malemedicine.medical_treatmentBrachytherapyBrachytherapyIodine RadioisotopesProstate cancerProstatemedicineHumansDosimetryRadiology Nuclear Medicine and imagingRadiometryAgedRetrospective StudiesIndex Lesionmedicine.diagnostic_testbusiness.industryProstateProstatic NeoplasmsRadiotherapy DosageMagnetic resonance imagingHematologyMiddle AgedProstate-Specific Antigenmedicine.diseaseMagnetic Resonance ImagingProstate-specific antigenTreatment Outcomemedicine.anatomical_structureOncologyTomography X-Ray ComputedNuclear medicinebusinessProstate brachytherapyFollow-Up StudiesRadiotherapy and Oncology
researchProduct

Focal or whole-gland salvage prostate brachytherapy with iodine seeds with or without a rectal spacer for postradiotherapy local failure: How best to…

2016

International audience; PURPOSE: Salvage prostate permanent implant (sPPI) for postradiation local failure provides high rates of biochemical control. The cumulative dose delivered to the prostate and the rectum is still unknown. METHODS AND MATERIALS: We reviewed the postimplant CT-based dosimetry of 18 selected patients who underwent sPPI with I-125 seeds for isolated biopsy-proven local failure several years after external beam radiation therapy. Ten patients had whole-prostate sPPI, and 8 patients had multiparametric MRI-based focal sPPI. In 8 patients, hyaluronic acid (HA) gel was injected into the prostate rectum space. RESULTS: The median cumulative biological effective dose after EB…

MaleOrgans at Risk[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatmentBrachytherapySalvage therapyRecommendationsAlpha/Beta030218 nuclear medicine & medical imaging[ SDV.CAN ] Life Sciences [q-bio]/Cancer[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicineIodine RadioisotopesBiologically effective doseProstate cancer0302 clinical medicineProstatePositron Emission Tomography Computed Tomography[ SDV.IB ] Life Sciences [q-bio]/BioengineeringHyaluronic Acid[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingProstate cancerCumulative doseCancer RecurrencesRadiotherapy DosageMenLow dose rateMiddle AgedImplantation3. Good healthmedicine.anatomical_structureOncology030220 oncology & carcinogenesis[SDV.IB]Life Sciences [q-bio]/BioengineeringLocal failureProstate brachytherapymedicine.medical_specialtyBrachytherapyRectum[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineRadiation Dosage03 medical and health sciencesPermanent BrachytherapymedicineHumansProctitisRadiology Nuclear Medicine and imagingRadiation InjuriesProctitisAgedSalvage TherapySalvage brachytherapyRadiotherapybusiness.industryRadiotherapy Planning Computer-AssistedCarcinomaRectumProstatic Neoplasmsmedicine.diseaseRadiation-TherapySurgeryNeoplasm Recurrence LocalTomography X-Ray ComputedNuclear medicinebusinessGels
researchProduct

Pattern of occult nodal relapse diagnosed with 18F-fluoro-choline PET/CT in prostate cancer patients with biochemical failure after prostate-only rad…

2014

Abstract Introduction The purpose of this study was to describe the pattern of nodal relapse with 18 F-fluoro-choline (FCH) Positron Emission Tomography/Computerized Tomography (PET/CT) in prostate cancer patients after radiotherapy. Materials and methods Eighty-three patients had a FCH PET/CT at time of biochemical failure. Of 65 patients with positive findings, 33 had positive nodes. This analysis included 31 patients who had undergone prior prostate-only radiotherapy with or without a prior radical prostatectomy. Each FCH positive node was assigned to a lymph node station with respect to the CTV defined by the RTOG guidelines (CTV RTOG ). 3D mapping was performed after each node was manu…

MaleFluorine Radioisotopesmedicine.medical_treatment[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineMultimodal Imaging[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicineCholineProstate cancerProstatemedicineHumansRadiology Nuclear Medicine and imagingLymph nodeComputingMilieux_MISCELLANEOUSSalvage TherapyPET-CTmedicine.diagnostic_testProstatectomybusiness.industryProstatic NeoplasmsHematologyProstate-Specific Antigenmedicine.diseaseOccult3. Good healthRadiation therapymedicine.anatomical_structureOncologyPositron emission tomographyLymphatic MetastasisPositron-Emission TomographyKallikreinsLymph NodesNeoplasm Recurrence LocalRadiopharmaceuticalsNuclear medicinebusinessTomography X-Ray Computed
researchProduct

Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic age…

2011

Abstract Purpose. A better identification of patients who are more likely to benefit from vascular endothelial growth factor–targeted therapy is warranted in metastatic renal cell carcinoma (mRCC). As adipose tissue releases angiogenic factors, we determined whether parameters such as visceral fat area (VFA) were associated with outcome in these patients. Experimental Design. In 113 patients with mRCC who received antiangiogenic agents (bevacizumab, sunitinib, or sorafenib) (n = 64) or cytokines (n = 49) as first-line treatment, we used computed tomography to measure VFA and subcutaneous fat area (SFA). We evaluated associations linking body mass index (BMI), SFA, and VFA to time to progres…

SorafenibOncologyMaleCancer Researchmedicine.medical_specialtygenetic structuresIntra-Abdominal FatBevacizumabPopulationAngiogenesis InhibitorsIntra-Abdominal FatCohort StudiesGenitourinary Cancer: Renal Bladder and TesticularRenal cell carcinomaInternal medicinemedicineHumansNeoplasm MetastasiseducationSurvival rateCarcinoma Renal CellAgedRetrospective Studieseducation.field_of_studyNeovascularization PathologicSunitinibbusiness.industrymedicine.diseasePrognosisKidney NeoplasmsSurvival RateEndocrinologyTreatment OutcomeOncologyDisease ProgressionFemalebusinessBody mass indexmedicine.drugThe oncologist
researchProduct

Automatic Evaluation of Histological Prognostic Factors Using Two Consecutive Convolutional Neural Networks on Kidney Samples

2022

BACKGROUND AND OBJECTIVES: The prognosis of patients undergoing kidney tumor resection or kidney donation is linked to many histologic criteria. These criteria notably include glomerular density, glomerular volume, vascular luminal stenosis, and severity of interstitial fibrosis/tubular atrophy. Automated measurements through a deep-learning approach could save time and provide more precise data. This work aimed to develop a free tool to automatically obtain kidney histologic prognostic features. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In total, 241 samples of healthy kidney tissue were split into three independent cohorts. The “Training” cohort (n=65) was used to train two convoluti…

AdultMalemedicine.medical_specialtyEpidemiologyTubular atrophyUrologyKidneyCritical Care and Intensive Care MedicineConvolutional neural networkCortex (anatomy)medicineHumansAgedTransplantationKidneybusiness.industryDeep learningArea under the curveMiddle AgedPrognosismedicine.diseaseKidney NeoplasmsStenosismedicine.anatomical_structureNephrologyCohortOriginal ArticleFemaleNeural Networks ComputerArtificial intelligencebusinessClinical Journal of the American Society of Nephrology
researchProduct

Traitement du cancer de la prostate : comment les patients font-ils leur choix ?

2013

Resume Le cancer de la prostate demeure un probleme de sante publique en France chez les hommes de 50 a 70 ans. Pour le cancer localise de la prostate de bon pronostic ou de pronostic intermediaire, il existe une pluralite de possibilites therapeutiques. Objectif. Identifier, dans le discours des patients, les mecanismes et les logiques intervenant dans la decision therapeutique. Methode. etude qualitative aupres de 15 hommes âges de 53 a 70 ans, traites pour un cancer de la prostate de stade precoce, par entretiens abordant l’itineraire diagnostique, la representation et le vecu de la maladie, les facteurs decisionnels en matiere de traitement. Resultats. Les hommes ont elabore leur choix …

GynecologyCancer Researchmedicine.medical_specialtyOncologybusiness.industryMedicineRadiology Nuclear Medicine and imagingHematologyGeneral MedicinebusinessBulletin du Cancer
researchProduct

EARLY CHOLINE LEVELS FROM 3-TESLA MR SPECTROSCOPY AFTER EXCLUSIVE RADIATION THERAPY IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER ARE PREDICT…

2011

International audience; Abstract: Purpose: To investigate the time course response of prostate metabolism to irradiation using magnetic resonance spectroscopy (MRS) at 3-month intervals and its impact on biochemical control. Methods and Materials: Between January 2008 and April 2010, 24 patients with localized prostate cancer were prospectively enrolled in the Evaluation of the Response to Irradiation with MR Spectroscopy (ERIS) trial. All the patients had been treated with intensity-modulated radiation therapy with or without long-term adjuvant hormonal therapy (LTHT) and underwent 3-T MRS and prostate-specific antigen (PSA) assays at baseline and every 3 months thereafter up to 12 months.…

MaleIn vivo magnetic resonance spectroscopyCancer ResearchTime Factorsmedicine.medical_treatmentCholine030218 nuclear medicine & medical imagingchemistry.chemical_compoundProstate cancer0302 clinical medicineProstateCholineProspective StudiesProspective cohort studyProstate cancerRadiation[ INFO.INFO-IM ] Computer Science [cs]/Medical ImagingProstateOrgan SizeMiddle AgedTumor Burdenmedicine.anatomical_structureOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisPredictive value of testsHormonal therapyResponse monitoringmedicine.medical_specialtyUrologyCitric Acid03 medical and health sciencesBody WaterPredictive Value of TestsMagnetic resonance spectroscopymedicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingHumansRadiology Nuclear Medicine and imagingAgedbusiness.industryProstatic NeoplasmsAndrogen AntagonistsProstate-Specific Antigenmedicine.diseaseRadiation therapychemistryRadiotherapy Intensity-Modulated3 TeslabusinessNuclear medicine
researchProduct

Le robot améliore-t-il la prostatectomie totale laparoscopique dans les cas complexes ?

2010

Resume La prostatectomie totale est le traitement de reference du cancer de prostate de l’homme jeune. Mais dans les cas difficiles, les patients peuvent etre orientes vers une autre option therapeutique. Objectif Evaluation de la qualite de l’anastomose dans les cas complexes de chirurgie comparant la voie laparoscopique PTL a la voie laparoscopique assistee du robot PTLR. Materiel Trois cent quatre-vingt dix-sept patients ont ete operes de mars 2004 a aout 2009, 176 PTL et 221 PTLR de maniere consecutive par un meme chirurgien. Les antecedents pouvant compliquer le geste chirurgical ont ete analyses : volume prostatique superieur a 80 cc, antecedent de cure de hernie inguinale avec prothe…

Gynecologymedicine.medical_specialtybusiness.industryUrologymedicinebusinessProgrès en Urologie
researchProduct

Inferring postimplant dose distribution of salvage permanent prostate implant (PPI) after primary PPI on CT images

2018

International audience; PURPOSE:To evaluate the dose distribution of additional radioactive seeds implanted during salvage permanent prostate implant (sPPI) after a primary permanent prostate implant (pPPI).METHODS AND MATERIALS:Patients with localized prostate cancer were primarily implanted with iodine-125 seeds and had a dosimetric assessment based on day 30 postimplant CT (CT1). After an average of 6 years, these patients underwent sPPI followed by the same CT-based evaluation of dosimetry (CT2). Radioactive seeds on each CT were detected. The detected primary seeds on CT1 and CT2 were registered and then removed from CT2 referred as a modified CT2 (mCT2). Dosimetry evaluations (D90 and…

MaleBrachytherapy[SDV.CAN]Life Sciences [q-bio]/CancerDose distribution[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology030218 nuclear medicine & medical imagingIodine Radioisotopes03 medical and health sciencesProstate cancer0302 clinical medicineProstateDosimetryIodine seedsmedicineHumansDosimetryRadiology Nuclear Medicine and imagingRadiometrySalvage TherapyPrimary permanentSalvage brachytherapyProstate cancerbusiness.industryProstateProstatic NeoplasmsProstate implantRadiotherapy Dosagemedicine.disease3. Good healthmedicine.anatomical_structureOncology030220 oncology & carcinogenesisTomography X-Ray ComputedbusinessNuclear medicineSalvage brachytherapy[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Transcatheter embolization of a renal artery pseudoaneurysm after open partial nephrectomy.

2011

Twelve days after an open partial nephrectomy, a 31-year-old man was re-admitted urgently for acute lumbar pain. An emergent helical computed tomography scan with intravenous contrast revealed a 3-cm renal artery pseudoaneurysm at the site of the partial nephrectomy, which was responsible for a large perirenal hematoma. Transarterial hyperselective embolization successfully occluded the pseudoaneurysm with less than 1 mL of N-butyl-2-cyanoacrylate, an embolizing agent less costly than coils. The kidney parenchyma was fully preserved.

AdultMalemedicine.medical_specialtymedicine.medical_treatmentContrast MediaNephrectomyPseudoaneurysmLumbarRenal Arterymedicine.arteryMedicineHumanscardiovascular diseasesEmbolizationRenal arteryKidneybusiness.industryAngiographyGeneral MedicineEnbucrilatemedicine.diseaseEmbolization TherapeuticNephrectomySurgeryClear cell renal cell carcinomamedicine.anatomical_structureTreatment Outcomecardiovascular systemPerirenal hematomaSurgeryTissue AdhesivesRadiologybusinessTomography X-Ray ComputedAneurysm FalseAmerican journal of surgery
researchProduct

Évaluation par questionnaire des pratiques de la curiethérapie de prostate en France

2017

Resume Introduction La curietherapie des cancers de la prostate s’est progressivement implantee dans l’arsenal therapeutique comme une alternative a la prostatectomie radicale et a la radiotherapie externe. Dans le groupe des patients presentant un cancer de pronostic favorable, les survies specifiques depassent 95 % a 10 ans. L’objectif de cette etude est de decrire la place actuelle et les pratiques de la curietherapie en France. Materiel et methodes Un questionnaire realise en association avec l’Association francaise d’urologie (AFU) et la Societe francaise de radiotherapie oncologique (SFRO) et evaluant les differentes pratiques de la curietherapie en France a ete adresse a tous les uro…

Gynecologymedicine.medical_specialtyPracticebusiness.industryUrology[SDV]Life Sciences [q-bio]Brachytherapy030232 urology & nephrologyProstate3. Good health03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisCuriethérapiemedicineFrancePratiquesbusinessSurvey
researchProduct

Computer-aided diagnosis system for characterizing ISUP grade≥2 prostate cancers at multiparametric MRI: A cross-vendor evaluation.

2019

International audience; Purpose: To assess the performance of a computer-aided diagnosis (CADx) system trained at characterizing International Society of Urological Pathology (ISUP) grade >= 2 peripheral zone (PZ) prostate cancers on multiparametric magnetic resonance imaging (mpMRI) examinations from a different institution and acquired on different scanners than those used for the training database.Patients and methods: Preoperative mpMRIs of 74 men (median age, 65.7 years) treated by prostatectomy between 2014 and 2017 were retrospectively selected. One radiologist outlined suspicious lesions and scored them using Prostate Imaging-Reporting and Data System version 2 (PI-RADSv2); their CA…

MaleStandardsmedicine.medical_specialtyComputer-assisted diagnosis[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatmentDiagnostic accuracy[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineSensitivity and Specificity[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineProstateDiagnosisValidationImage Interpretation Computer-AssistedmedicineHumansRadiology Nuclear Medicine and imagingMagnetic resonance imaging (MRI)Diagnosis Computer-AssistedMultiparametric Magnetic Resonance ImagingAgedRetrospective StudiesProstatectomyPeripheral zoneRadiological and Ultrasound TechnologyReceiver operating characteristicbusiness.industryProstatectomyPI-RADS V2Multiparametric MRIProstatic NeoplasmsGeneral MedicineConfidence interval3. Good health[SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/Imagingmedicine.anatomical_structureComputer-aided diagnosis030220 oncology & carcinogenesisCohortImagesRadiologybusinessDiagnostic and interventional imaging
researchProduct

18F-Choline PET/CT and multiparametric MRI for the detection of local recurrence of prostate cancer initially treated by radiotherapy: comparison wit…

2016

International audience

[SDV.IB] Life Sciences [q-bio]/Bioengineering[SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/Imaging[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging[SDV.IB]Life Sciences [q-bio]/Bioengineering[ SDV.IB ] Life Sciences [q-bio]/Bioengineering[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingComputingMilieux_MISCELLANEOUS[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine
researchProduct

Correlation between clinical prognostic factors and MR spectroscopy-based biomarkers determined at 3.0 T without endorectal coils for patients with l…

2009

International audience

[ INFO.INFO-IM ] Computer Science [cs]/Medical Imaging[INFO.INFO-IM]Computer Science [cs]/Medical Imaging[INFO.INFO-IM] Computer Science [cs]/Medical ImagingComputingMilieux_MISCELLANEOUS
researchProduct

Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxe…

2010

There is currently no standard of treatment for patients with hormone refractory prostate cancer (HRPC) after failure of docetaxel-based chemotherapy. The purpose of this study was to assess the anticancer activity and tolerance of metronomic cyclophosphamide prednisolone combination in this setting.From 2005 to 2010, patients with HRPC who failed at least docetaxel-based chemotherapy were proposed metronomic cyclophosphamide-prednisolone regimen, and were prospectively registered. Twenty-three patients received 50 mg cyclophosphamide and 10 mg prednisolone per os daily until disease progression. Treatment tolerance and efficacy on PSA decrease and pain were studied.Metronomic cyclophospham…

Male[SDV.IMM] Life Sciences [q-bio]/ImmunologyMESH : Antineoplastic Combined Chemotherapy ProtocolsMESH: Treatment FailurePrednisoloneMESH : MaleMESH : PrednisoloneMESH: TaxoidsMESH : AgedMESH : Prospective StudiesDocetaxelMESH : Treatment OutcomeMESH : Treatment FailureMESH: Aged 80 and overAntineoplastic Combined Chemotherapy ProtocolsHumans[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyMESH : Middle AgedProspective StudiesTreatment FailureMESH : Prostate-Specific AntigenMESH : Aged 80 and overMESH : TaxoidsCyclophosphamideMESH : Cyclophosphamidehealth care economics and organizationsAgedMESH: Treatment OutcomeAged 80 and overMESH: AgedMESH: HumansMESH: Middle AgedMESH : HumansProstatic NeoplasmsMESH: CyclophosphamideMiddle AgedProstate-Specific AntigenMESH: MaleMESH: Prospective StudiesMESH: Prostate-Specific AntigenMESH: Antineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeMESH: Prostatic Neoplasms[SDV.IMM]Life Sciences [q-bio]/ImmunologyTaxoidsMESH: PrednisoloneMESH : Prostatic Neoplasms
researchProduct